Table 3 Model evaluation by LSSA and RNA-sequencing analysis (Chemoth stands for chemotherapy)
From: p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification
Source scenario in patients | Target scenario in patients | LSSA simulation | Total number of genes | Number of correct predictions | p-value of correct predictions | Number of small error predictions | Number of large error predictions |
|---|---|---|---|---|---|---|---|
TP53 wild type treated with chemoth | TP53 mutant treated with chemoth | TP53 null with DNA damage ON vs TP53 wt with DNA damage ON | 200 | 104 (52%) | 2.03 × 10−8 | 90 (45%) | 6 (3%) |
TP53 wild type not treated with chemoth | TP53 mutant not treated with chemoth | TP53 null with DNA damage OFF vs TP53 wt with DNA damage OFF | 200 | 109 (54.5%) | 3.77 × 10−10 | 86 (43%) | 5 (2.5%) |
TP53 mutant not treated with chemoth | TP53 mutant treated with chemoth | TP53 null with DNA damage ON vs TP53 null with DNA damage OFF | 200 | 150 (75%) | 1.92 × 10−33 | 46 (23%) | 4 (2%) |
TP53 wild type not treated with chemoth | TP53 wild type treated with chemoth | TP53 wt with DNA damage ON vs TP53 wt with DNA damage OFF | 200 | 168 (84%) | 1.921.92 × 10−49 | 31 (15.5%) | 1 (0.5%) |